We are international

ASH 2006 - Webcasts
    next      view all

ASH Overview
12.23.07   Overview of ASH 2006 in Czech
Prof. Roman Hájek
Masaryk University
Brno, Czech Republic

12.17.07   Ein Überblick über den ASH-Kongress
Hartmut Goldschmidt, MD
Universitätsklinikum Heidelberg (University Clinic of Heidelberg) und Nationales Centrum für Tumorerkrankungen (and the National Center of Tumor Diseases)
Heidelberg, Deutschland

Novel Agents - Newly-Diagnosed Myeloma
12.17.06   A Randomized Study of Lenalidomide with High- or Low-Dose Dexamethasone in the Treatment of Newly Diagnosed Myeloma
S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, MN

12.17.06   An International Randomized Trial of Thal/Dex vs Dexamethasone Alone
S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, MN

12.17.06   An Overview of Planned Randomized Clinical Trials for Newly Diagnosed Younger and Older Patients in Spain
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain

12.17.06   Analysis of Phase III Study of Revlimid + Dexamethasone in Patients >65 Years
Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY

12.17.06   Breaking the Plateau Response in MM: Results of a Pilot Study of Vel/Dex/Doxil (DoVeD)
Ruben Niesvizky, MD
New Presbyterian Hospital
Weill Cornell Medical Center
New York, NY

12.17.06   Identification of Mutations in the NFkB Pathway That Predict Velcade Response
A. Keith Stewart, MD
Mayo Clinic
Scottsdale, AZ

12.17.06   Long Term Results of a Study of Rev/Dex in Newly Diagnosed Patients
Martha Q. Lacy, MD
Mayo Clinic
Rochester, MN

12.17.06   Long-Term Follow-Up of a Phase II Trial of Vel/Dex in Frontline Therapy for Myeloma
Sundar Jagannath, MD
St. Vincent’s Comprehensive Cancer Center
New York, NY

    next      view all